NAD+ (nicotinamide adenine dinucleotide) is one of the most important molecules in human biology. It is essential for energy metabolism, DNA repair, sirtuin activation, and hundreds of enzymatic reactions. The problem: NAD+ levels decline significantly with age. By 50, you may have half the NAD+ you had at 20. This decline is now considered a hallmark of aging, and an entire supplement industry has emerged around reversing it.

The two leading contenders are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are NAD+ precursors -- meaning the body converts them into NAD+. But they take different biochemical routes, have different champions, different price points, and generate very different levels of controversy. This article breaks down what the evidence actually shows.

The biochemistry: how each becomes NAD+

NR and NMN sit at adjacent steps in the NAD+ biosynthesis pathway. NR is converted to NMN by the enzyme nicotinamide riboside kinase (NRK1/NRK2), and NMN is then converted to NAD+ by the enzyme NMNAT. So NR must first become NMN before it can become NAD+. This led early NMN advocates to argue that NMN is "one step closer" to NAD+ and therefore more efficient.

However, cellular biology is rarely that simple. NMN is a larger molecule (334 Da vs 255 Da for NR) and its ability to cross cell membranes directly was debated for years. In 2019, a dedicated NMN transporter (Slc12a8) was identified in the gut (Grozio et al., Nature Metabolism), though some researchers have questioned how significant this transporter is in other tissues. NR, being smaller, enters cells more readily and is phosphorylated to NMN intracellularly.

The practical takeaway: both molecules reliably raise NAD+ levels in humans, through slightly different routes. The "one step closer" argument for NMN is an oversimplification.

Human trial data: what we actually know

NR has a significant head start in clinical research. ChromaDex, the company behind Tru Niagen, has funded multiple human trials. A 2018 randomized controlled trial (Martens et al., Nature Communications) showed that 1,000 mg/day of NR for 6 weeks increased NAD+ levels by approximately 60% in healthy middle-aged and older adults. A 2023 trial showed NR supplementation improved markers of mitochondrial function and reduced inflammatory cytokines in older adults.

NMN human data has been catching up rapidly. A 2022 randomized, double-blind trial (Yi et al., Science) demonstrated that 250 mg/day of NMN increased blood NAD+ levels and improved muscle insulin sensitivity in prediabetic women over 10 weeks. A 2024 multi-center RCT in Japan showed 250 mg NMN daily improved aerobic capacity and biological age markers in healthy adults aged 40-65.

The honest comparison: NR currently has more published human RCTs, largely because ChromaDex invested heavily in clinical research early. NMN data is growing and looks promising. Neither molecule has long-term (5+ year) human safety or efficacy data.

The bioavailability debate

This is where the discussion gets heated. NMN proponents argue that the Slc12a8 transporter allows direct absorption, bypassing the need for conversion. NR advocates counter that NR is well-characterized for oral bioavailability and that NMN is partially degraded to NR in the gut anyway (Liu et al., 2023, Cell Metabolism), meaning some NMN you take orally ends up being converted to NR before absorption.

A 2023 pharmacokinetic study comparing equimolar oral doses of NMN and NR found both raised whole-blood NAD+ levels by similar magnitudes over 8 hours, with NR showing slightly faster peak levels and NMN showing a slightly more sustained elevation. The differences were modest and the study was small (n=36).

Sublingual and liposomal delivery formats for NMN have emerged, claiming to bypass gut degradation. These formats lack comparative clinical trials, so claims of superiority remain theoretical.

The Sinclair factor

Any honest discussion of NMN must address David Sinclair, the Harvard genetics professor whose research and public advocacy have been the primary driver of NMN's popularity. Sinclair's lab produced foundational NAD+ research, and his book "Lifespan" brought NMN to mass awareness.

The controversy: Sinclair has financial ties to NMN-related companies and has made bold public claims about his personal regimen reversing his biological age. Some scientists have criticized these claims as going beyond what his published data supports. A 2023 investigation by Science raised questions about image manipulation in some of his lab's earlier papers, though these were in cell biology, not directly in the NMN clinical work.

What this means for consumers: Sinclair's scientific contributions to the NAD+ field are genuine and substantial. However, his dual role as researcher and commercial advocate means his public claims should be weighed against the broader evidence base, not taken as standalone proof. The NMN research is bigger than one lab.

Cost comparison

NMN is generally more expensive than NR. As of early 2026:

  • NR (Tru Niagen, 300mg/day): approximately $40-50/month
  • NMN (reputable brands, 250-500mg/day): approximately $40-80/month depending on dose and brand
  • NMN (bulk powder, less convenient): approximately $25-40/month

The cost gap has narrowed considerably since 2023, when NMN was 2-3x more expensive. NMN's regulatory status has also been complex -- the FDA briefly considered classifying it as an investigational drug rather than a supplement, though this has not resulted in a market ban.

Which one actually raises NAD+ more?

Based on current evidence, the answer is frustratingly close to "about the same at equivalent doses." Head-to-head comparisons show similar NAD+ elevation. The practical differences are more about format, cost, and personal preference than dramatic efficacy gaps.

If forced to choose based purely on current evidence strength: NR has a more established clinical dossier. NMN has strong mechanistic arguments and rapidly growing human data. Neither is clearly superior.

Our take

Both NMN and NR are legitimate NAD+ precursors with real evidence behind them. The supplement industry has turned this into a tribal war, but the science does not support strong allegiance to either side. What matters more than the specific precursor is: (1) choosing a reputable, third-party tested product, (2) using evidence-based doses (typically 250-1,000 mg/day for NMN, 300-1,000 mg/day for NR), and (3) having realistic expectations -- NAD+ precursors are promising longevity tools, not proven life-extension drugs.

If you are already taking one and tolerating it well, there is no compelling reason to switch. If you are starting fresh, NR has the longer clinical track record; NMN has the momentum and a growing evidence base. Both are reasonable choices. Neither is a magic pill.